Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide to Prevent Pulmonary Graft Dysfunction After Transplant (Pilot RCT)
2004-004928-12Phase 3Completed
- Sponsor
- INO Therapeutics
- Start
- Nov 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nitric oxide in primary graft dysfunction (PGD) (2 arms), sponsored by INO Therapeutics. Primary endpoint: Pulmonary graft dysfunction incidence. Started Nov 2005; status: completed.
02
Drugs
nitric oxide
03
Conditions
primary graft dysfunction (PGD)
Beyond the preview
Go deeper on 2004-004928-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004928-12.